Health holland awards innovative research grant for dna pol iiic inhibitors to leiden university medical center and acurx pharmaceuticals

Staten island, n.y., aug. 2, 2021 /prnewswire/ -- acurx pharmaceuticals, inc. (nasdaq acxp) ("acurx" or the "company") a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that health holland has awarded a grant of approximately $500,000 usd to leiden university medical center (lumc) and, through a three-party consortium agreement, acurx pharmaceuticals.
ACXP Ratings Summary
ACXP Quant Ranking